The Immunologic Monitoring and Cellular Products Laboratory (IMCPL) is the UPCI shared facility responsible for therapeutic cell product generation (CPL) and for serial monitoring of immunologic functions in patients with cancer who are treated with biologic therapies (IML). The IMCPL has been playing an important role in supporting novel investigator-initiated immunotherapy trials at the UPCI. 75% of its usage is cancer-related. CPL makes quality products for tumor vaccines and for cellular and gene therapy of cancer using Current Good Manufacturing Practice and Good Tissue Practice (cGMP/cGTP) conditions. In 2008, the CPL component of IMCPL provided services to clinical or research protocols, performing 11,793 procedures, which varied in complexity from large-scale therapeutic products and smaller cultures for pre-clinical studies to piloting new cell products and help in the preparation of investigational New Drugs (INDs). The IML makes available to users a broad range of state-of-the-art immunologic monitoring assays performed under a rigorous quality control program. A total of 54,588 tests were performed for clinical or research studies in 2008. These included phenotyping of immune cells, single-cell assays (ELISPOT, tetramer analysis and cytokine flow cytometry) for vaccine monitoring, and population-based assays for cell proliferation by flow cytometry (CFSE), cytokine profiling by Luminex, cytotoxicity, apoptosis, and T-cell signaling. The IMCPL maintains a Research and Development program designed for new product/assay development, evaluation and standardization. Advice to users about cell product/test selection and result interpretations are also a part ofthe IMCPL responsibilities. The IMCPL has an independently-monitored and extensive quality control (QC) and quality assurance (QA) program to ensure the validity of test results and safety/quality of therapeutic products. The IMCPL has established a fee-for-service schedule and gives priority as well as discounted fees to the UPCI members. High quality of cellular products and reproducibility of the assays performed by the IMPCL for the UPCI programs contribute to the overall excellence of clinical and research studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-26
Application #
8705414
Study Section
Special Emphasis Panel (ZCA1-RTRB-L)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
26
Fiscal Year
2014
Total Cost
$421,214
Indirect Cost
$142,569
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Chen, Lin; Vasilatos, Shauna N; Qin, Ye et al. (2017) Functional characterization of lysine-specific demethylase 2 (LSD2/KDM1B) in breast cancer progression. Oncotarget 8:81737-81753
Kurland, Brenda F; Linden, Hannah M; Mankoff, David A (2017) FDG PET and FES PET Predict PFS on Endocrine Therapy-Response. Clin Cancer Res 23:3475
Jing, Y; Nguyen, M M; Wang, D et al. (2017) DHX15 promotes prostate cancer progression by stimulating Siah2-mediated ubiquitination of androgen receptor. Oncogene :
Lee-Montiel, Felipe T; George, Subin M; Gough, Albert H et al. (2017) Control of oxygen tension recapitulates zone-specific functions in human liver microphysiology systems. Exp Biol Med (Maywood) 242:1617-1632
Gao, Ying; Li, Changling; Wei, Leizhen et al. (2017) SSRP1 Cooperates with PARP and XRCC1 to Facilitate Single-Strand DNA Break Repair by Chromatin Priming. Cancer Res 77:2674-2685
Xie, Yangchun; Zhu, Shan; Zhong, Meizuo et al. (2017) Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma. Gastroenterology 153:1429-1443.e5
von Gruenigen, Vivian E; Huang, Helen Q; Beumer, Jan H et al. (2017) Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study. Gynecol Oncol 144:459-467
Pascal, Laura E; Masoodi, Khalid Z; Liu, June et al. (2017) Conditional deletion of ELL2 induces murine prostate intraepithelial neoplasia. J Endocrinol 235:123-136
Tarhini, Ahmad A; Rafique, Imran; Floros, Theofanis et al. (2017) Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer. Cancer 123:2936-2944
Lothet, Emilie H; Shaw, Kendrick M; Lu, Hui et al. (2017) Selective inhibition of small-diameter axons using infrared light. Sci Rep 7:3275

Showing the most recent 10 out of 1045 publications